Inventor · disambiguated record
Teemu T. Junttila
Also filed as: JUNTTILA TEEMU T · JUNTTILA TEEMU TAPANI
12 granted patents·10 pending applications·11 citations·filing 2014–2025
86Inventor score
Top patents by PatentIndex Score
22 records- 0187US10640572B2Anti-CD3 antibodies and methods of useGENENTECH INC·Filed 2017·Granted May 5, 2020·2 cites·18 claims
- 0285US11732054B2Anti-CD3 antibodies and methods of useGENENTECH INC·Filed 2020·Granted Aug 22, 2023·1 cites·56 claims
- 0385US11530275B2Anti-CD3 antibodies and methods of useGENENTECH INC·Filed 2020·Granted Dec 20, 2022·1 cites·20 claims
- 0485US2024383984A1HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USEGENENTECH INC·Filed 2024·Application pending·0 cites
- 0583US12049515B2Agonistic CD28 antigen binding molecules targeting Her2HOFFMANN LA ROCHE·Filed 2021·Granted Jul 30, 2024·1 cites·37 claims
- 0679US10323094B2Humanized and affinity matured antibodies to FcRH5 and methods of useGENENTECH INC·Filed 2016·Granted Jun 18, 2019·2 cites·24 claims
- 0778US12297270B2Bispecific antigen-binding molecules and methods of useGENENTECH INC·Filed 2023·Granted May 13, 2025·0 cites·36 claims
- 0877US12030947B2Humanized and affinity matured antibodies to FcRH5 and methods of useGENENTECH INC·Filed 2021·Granted Jul 9, 2024·0 cites·70 claims
- 0977US10435471B2Anti-FcRH5 antibodiesGENENTECH INC·Filed 2014·Granted Oct 8, 2019·3 cites·49 claims
- 1076US2025066448A1Her2-targeting antigen binding molecules comprising 4-1bblHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1175US11866498B2Bispecific antigen-binding molecules and methods of useGENENTECH INC·Filed 2019·Granted Jan 9, 2024·1 cites·24 claims
- 1274US2023096941A1Anti-fcrh5 antibodiesGENENTECH INC·Filed 2022·Application pending·0 cites
- 1372US11192950B2Humanized and affinity matured antibodies to FcRH5 and methods of useGENENTECH INC·Filed 2019·Granted Dec 7, 2021·0 cites·38 claims
- 1471US2025059298A1Agonistic cd28 antigen binding molecules targeting her2HOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1570US11352431B2Anti-FCRH5 antibodiesGENENTECH INC·Filed 2019·Granted Jun 7, 2022·0 cites·20 claims
- 1668US2025129162A1Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2024·Application pending·0 cites
- 1767US12065478B2HER2-targeting antigen binding molecules comprising 4-1BBLHOFFMANN LA ROCHE·Filed 2020·Granted Aug 20, 2024·0 cites·11 claims
- 1863US2017008971A1Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodiesGENENTECH INC·Filed 2016·Application pending·0 cites
- 1963US2024360229A1Multispecific antibodies and uses thereofGENENTECH INC·Filed 2024·Application pending·0 cites
- 2051US2022098325A1Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mabGENENTECH INC·Filed 2021·Application pending·0 cites
- 2145US2025320298A1Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2025·Application pending·0 cites
- 2245US2025205309A1Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and fcrh5xcd3 bispecific antibodies for the treatment of blood cancersGENENTECH INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Teemu T. Junttila files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →